Literature DB >> 23243634

Remestemcel-L, the first cellular therapy product for the treatment of graft-versus-host disease.

A Daly1.   

Abstract

Acute graft-versus-host disease (GVHD) is a cause of substantial morbidity and mortality following allogeneic stem cell transplantation. Complete responses to steroid-based front-line treatment occur in 25-40% of patients, and results of second-line treatment are unsatisfactory. This review examines the biological effects of mesenchymal stromal cells (MSCs) in relation to GVHD and describes the clinical results of GVHD treatment with cultured MSCs and the proprietary cryopreserved MSCs known as remestemcel-L. Copyright 2012 Prous Science, S.A.U. or its licensors. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23243634     DOI： 10.1358/dot.2012.48.12.1885866

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN： 1699-3993            Impact factor:   2.245


  7 in total

1.  Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study.

Authors:  Kazuo Muroi; Koichi Miyamura; Masaya Okada; Takuya Yamashita; Makoto Murata; Takayuki Ishikawa; Naokuni Uike; Michihiro Hidaka; Ryoji Kobayashi; Masahiro Imamura; Junji Tanaka; Kazuteru Ohashi; Shuichi Taniguchi; Takashi Ikeda; Tetsuya Eto; Masaki Mori; Mariko Yamaoka; Keiya Ozawa
Journal:  Int J Hematol       Date:  2015-11-25       Impact factor: 2.490

2.  Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study.

Authors:  Kazuo Muroi; Koichi Miyamura; Kazuteru Ohashi; Makoto Murata; Tetsuya Eto; Naoki Kobayashi; Shuichi Taniguchi; Masahiro Imamura; Kiyoshi Ando; Shunichi Kato; Takehiko Mori; Takanori Teshima; Masaki Mori; Keiya Ozawa
Journal:  Int J Hematol       Date:  2013-07-17       Impact factor: 2.490

3.  Suspension-Expansion of Bone Marrow Results in Small Mesenchymal Stem Cells Exhibiting Increased Transpulmonary Passage Following Intravenous Administration.

Authors:  Andrea Zanetti; Michelle Grata; Emily B Etling; Regeant Panday; Flordeliza S Villanueva; Catalin Toma
Journal:  Tissue Eng Part C Methods       Date:  2015-03-03       Impact factor: 3.056

Review 4.  Insurance approval of mesenchymal stem cell for acute GVHD in Japan: need of follow up for some remaining concerns.

Authors:  Koichi Miyamura
Journal:  Int J Hematol       Date:  2016-01-12       Impact factor: 2.490

Review 5.  Mesenchymal Stem/Progenitor Cells: The Prospect of Human Clinical Translation.

Authors:  Dina Rady; Marwa M S Abbass; Aiah A El-Rashidy; Sara El Moshy; Israa Ahmed Radwan; Christof E Dörfer; Karim M Fawzy El-Sayed
Journal:  Stem Cells Int       Date:  2020-08-11       Impact factor: 5.443

Review 6.  Human umbilical cord-derived mesenchymal stem/stromal cells: a promising candidate for the development of advanced therapy medicinal products.

Authors:  Miryam Mebarki; Camille Abadie; Jérôme Larghero; Audrey Cras
Journal:  Stem Cell Res Ther       Date:  2021-02-26       Impact factor: 6.832

7.  Non-clinical assessment of safety, biodistribution and tumorigenicity of human mesenchymal stromal cells.

Authors:  Claudia Thäte; Christiane Woischwill; Gunda Brandenburg; Matthias Müller; Sonja Böhm; Joachim Baumgart
Journal:  Toxicol Rep       Date:  2021-11-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.